Kiniksa Announces U.S. FDA Acceptance of sBLA and Priority Review for Rilonacept in Recurrent Pericarditis
23. November 2020 08:00 ET
|
Kiniksa Pharmaceuticals, Ltd.
- PDUFA goal date of March 21, 2021 -- Filing based on positive data from RHAPSODY, which achieved its primary and all major secondary endpoints -- Rilonacept BLA for CAPS transferred to Kiniksa from...
Kiniksa Reports Third Quarter 2020 Financial Results and Highlights Recent Pipeline and Corporate Activity
05. November 2020 07:30 ET
|
Kiniksa Pharmaceuticals, Ltd.
Rilonacept commercial launch in recurrent pericarditis anticipated in 1H 2021, if approved by the FDAMavrilimumab Phase 2 trial in GCA achieved primary and secondary efficacy endpoints with...
Kiniksa Announces Upcoming Rilonacept Analyst Day
21. September 2020 08:00 ET
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a pipeline of clinical-stage assets designed to...
Kiniksa Presents Data on the Burden of Disease in Patients with Recurrent Pericarditis at the European Society of Cardiology Congress 2020
31. August 2020 08:00 ET
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and...
Kiniksa Announces U.S. Orphan Drug Designation for Rilonacept for the Treatment of Pericarditis
16. Juli 2020 07:30 ET
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, July 16, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and...
Kiniksa Announces Positive Data from Phase 3 Trial of Rilonacept in Recurrent Pericarditis (RHAPSODY)
29. Juni 2020 07:15 ET
|
Kiniksa Pharmaceuticals, Ltd.
Primary and all major secondary efficacy endpoints were highly statistically significant Rilonacept treatment resulted in a 96% reduction in risk of recurrent pericarditis events (primary efficacy...
Kiniksa Provides Timing of Second Half 2020 Clinical Data Readouts
10. Juni 2020 08:00 ET
|
Kiniksa Pharmaceuticals, Ltd.
- Rilonacept pivotal Phase 3 data in recurrent pericarditis expected in Q3 2020 - - Mavrilimumab Phase 2 data in GCA and KPL-404 Phase 1 data expected in Q4 2020 - - Management to provide a...
Kiniksa Reports First Quarter 2020 Financial Results and Highlights Recent Corporate and Pipeline Activity
28. April 2020 07:30 ET
|
Kiniksa Pharmaceuticals, Ltd.
– Financial guidance and clinical timelines for rilonacept, mavrilimumab, vixarelimab and KPL-404 remain intact amid COVID-19 pandemic –– Mavrilimumab treatment protocol in COVID-19 pneumonia and...
Kiniksa Highlights Phase 2 Study Data Showing the Corticosteroid-Sparing Effect of Rilonacept in Patients with Recurrent Pericarditis at the American College of Cardiology's 69th Annual Scientific Session
30. März 2020 07:30 ET
|
Kiniksa Pharmaceuticals, Ltd.
- Phase 2 study data show the potential for rilonacept treatment to eliminate or reduce the risk of corticosteroid-associated morbidity in recurrent pericarditis - - Enrollment complete for the...
Kiniksa Announces Breakthrough Therapy Designation for Rilonacept for the Treatment of Recurrent Pericarditis
20. November 2019 08:00 ET
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, Nov. 20, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and...